A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma
Latest Information Update: 25 Mar 2022
At a glance
- Drugs WP 1066 (Primary)
- Indications Brain metastases; Glioblastoma; Glioma
- Focus Adverse reactions; First in man
- 21 Mar 2022 Status changed from active, no longer recruiting to completed.
- 28 Jul 2021 Planned End Date changed from 1 Jul 2021 to 31 Jul 2022.
- 28 Jul 2021 Planned primary completion date changed from 1 Jul 2021 to 31 Jul 2022.